hotspot -WSS

hotspot

author：hotspot 2025-09-30 12:57:22 - browse：4

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： How Vertex's cystic fibrosis drug is changing patients' lives

entertainment

focus

WSS

Affordable Connectivity Program vital to health care, experts say

Why Congress must ban federal programs from using QALYs

Thermo Fisher plant for manufacturing gene therapies to expand

CommonSpirit Health keeps growing, even as it loses money

EF3 tornado rips through North Carolina amid extreme weather nationwide

Divers poised to search for children washed away in Pennsylvania flash flood

knowledge

hotspot

Gilead needs Arcellx more than ever

knowledge

Psychedelics group wrestles with new pharma identity

Judge rejects Trump's request to move Stormy Daniels hush

United colonoscopy coverage change 'may cost lives,' doctors say

Biotech stock slump in 2023: awaiting the turnaround

Malaria cases in Florida and Texas: Here’s what you need to know

EpiPen alternative approval delay highlights citizen petition issue

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Tesla recalling nearly 16,000 of its 2021

Drug repurposing or repositioning? The language matters

Hospitals struggle to profit from CAR

explore

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Winning ticket for $1 billion Powerball jackpot sold in California

CommonSpirit Health keeps growing, even as it loses money

Experts study whether long Covid risk adds up with each reinfection

Senate HELP committee spars over health care workforce policies

entertainment

Wikipedia

focus

entertainment